Krystal Biotech Shares Tumble 10% on Wider 2Q Loss

The commercial-stage biotechnology company widened its loss to $33.2 million, or $1.25 a share, for the second quarter ended June 30, from $28.1 million, or $1.10 a share, a year earlier.

Krystal Biotech posted a wider loss from operations and higher total operating expenses.

Chief Executive Krish Krishnan said 2023 is off to a good start, as the company received U.S. Food and Drug Administration approval for vyjuvek in the first half, among other events, and that it expects momentum to continue for the rest of the year.

Write to Denny Jacob at [email protected]